

Appendix Table 1: Treatment-emergent incidence of hypoglycemia during open-ended assessment period (week 30 through week 52)


Hypoglycemia				
	Non SFU background (n=159)		SFU background (n=99)	
	Exenatide QW	Exenatide BID→ Exenatide QW	Exenatide QW	Exenatide BID→ Exenatide QW
	N=79	N=80	N=49	N=50
Major (%)	0	0	0	0
Minor (%)	0	0	10.2	8.0

Appendix Table 2: Observed Antibody Titer

	Observed Antibody Titer					
	Not detectable	Low Titer		High Titer		
		1/25	1/125	1/625	1/3125	1/15625
Day 1						
Exenatide QW-only (n=146)	144 (99%)	2 (1%)	0	0	0	0
Exenatide BID (n=144)	140 (97%)	4 (3%)	0	0	0	0
Week 30						
Exenatide QW-only (n=127)	62 (49%)	37 (29%)	21 (17%)	5 (4%)	2 (2%)	0
Exenatide BID (n=130)	94 (72%)	27 (21%)	7 (5%)	1 (1%)	1 (1%)	0
Week 52						
Exenatide QW-only (n=119)	65 (55%)	29 (24%)	14 (12%)	6 (5%)	2 (2%)	3 (3%)
Exenatide BID → QW (n=121)	75 (62%)	29 (24%)	13 (11%)	3 (2%)	1 (1%)	0

Percentages may not add up to 100% due to rounding.

Appendix Figure 1. LSmean change from baseline A1C in patients with baseline A1C <9% or ≥ 9%.



Appendix Figure 2. A1C reduction following 52 weeks of treatment was similar among patients regardless of weight loss. BL = Baseline

